238 related articles for article (PubMed ID: 20397739)
1. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies.
Brunton S; Wang F; Edwards SB; Crucitti AS; Ossanna MJ; Walker DJ; Robinson MJ
Drug Saf; 2010 May; 33(5):393-407. PubMed ID: 20397739
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.
Choy EH; Mease PJ; Kajdasz DK; Wohlreich MM; Crits-Christoph P; Walker DJ; Chappell AS
Clin Rheumatol; 2009 Sep; 28(9):1035-44. PubMed ID: 19533210
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
6. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
7. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of duloxetine in patients with chronic low back pain.
Skljarevski V; Desaiah D; Liu-Seifert H; Zhang Q; Chappell AS; Detke MJ; Iyengar S; Atkinson JH; Backonja M
Spine (Phila Pa 1976); 2010 Jun; 35(13):E578-85. PubMed ID: 20461028
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety.
Hurley DJ; Turner CL; Yalcin I; Viktrup L; Baygani SK
Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):120-8. PubMed ID: 16188367
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
Hunziker ME; Suehs BT; Bettinger TL; Crismon ML
Clin Ther; 2005 Aug; 27(8):1126-43. PubMed ID: 16199241
[TBL] [Abstract][Full Text] [Related]
17. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Bailey RK; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Natl Med Assoc; 2006 Mar; 98(3):437-47. PubMed ID: 16573311
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
